immunology

AbbVie beats Q1 earnings with $15B revenue, accelerates $31B immunology drug guidance to 2026 from 2027. Stock down 10% YTD despite outperformance.

AbbVie and adMare BioInnovations award RIME Therapeutics the AbbVie Biotech Innovators Prize, providing lab space, equipment, and executive mentorship.

AbbVie awards RIME Therapeutics incubation support at Montreal's adMare Centre, providing laboratory space, equipment access, and mentorship for its inflammation-focused peptide platform.

argenx will report Q1 2026 financial results on May 7, 2026, offering investors insight into the immunology company's clinical progress and commercial trajectory.

Eli Lilly's oncology and immunology portfolios rival its blockbuster weight-loss drugs, positioning the company better than Novo Nordisk for long-term growth.

Clinical-stage biotech ENA Respiratory appoints Melissa Faris, GSK respiratory veteran, as independent director to strengthen governance during INNA-051 development.

Nurix Therapeutics reported Q1 2026 revenue of $6.3M (down 66% YoY) and $87.2M net loss, maintaining $540.7M cash while advancing bexobrutideg clinical program.

AbbVie maintains 10+ years of consecutive dividend increases despite Humira patent loss, buoyed by blockbuster drugs Skyrizi and Rinvoq projected to reach $50B by 2030.

Biogen partners with Alloy Therapeutics to advance antisense oligonucleotide therapies using the AntiClastic platform for multiple undisclosed disease indications.

Sanofi's lunsekimig met primary endpoints in Phase 2 asthma and nasal polyps trials but failed in atopic dermatitis, advancing respiratory programs with favorable safety.

Biogen acquires Apellis Pharmaceuticals for $5.6 billion in cash, gaining two FDA-approved therapies with $689M in 2025 projected sales and mid-to-high teens growth expectations.

Novartis acquires Excellergy for up to $2 billion to develop Exl-111, a next-generation anti-IgE allergy drug in Phase 1 trials, strengthening its immunology pipeline.

Novartis to acquire private biotech Excellergy for up to $2B, adding next-generation anti-IgE antibody Exl-111 targeting food allergy, chronic urticaria, and allergic asthma.

Apogee Therapeutics CEO sells $1.5M in shares via pre-planned program amid stock's 100% surge, but bullish clinical data and $350M capitalization warrant investor focus.

Quotient Therapeutics and Merck partner on IBD drug discovery, with Quotient receiving $20M upfront and up to $2.2B in milestones.

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.

Novartis presents 20+ abstracts at AAD 2026, highlighting rapid symptom relief with Rhapsido and long-term efficacy data for Cosentyx across multiple skin conditions.

Apogee Therapeutics to present 52-week Phase 2 data for APG777 in atopic dermatitis on March 23, 2026, signaling major clinical development milestone.

Tonix Pharmaceuticals CEO to present commercial CNS portfolio at BIO-Europe Spring 2026, showcasing TONMYA® fibromyalgia launch success with 1,500+ prescriptions since November 2025.

AbbVie's Skyrizi achieved 55% remission rate in Crohn's patients versus 30% placebo, strengthening competitive positioning against Johnson & Johnson's Tremfya.